The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …

Many discharged COVID-19 patients affected by sequelae experience reduced quality of life
leading to an increased burden on the healthcare system, their families and society at large …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

COVID-19, the disease responsible for the devastating pandemic that began at the end of
2019, has been associated with a significantly increased risk of pulmonary thrombosis, even …

Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …

Severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) is the causal
agent of coronavirus disease-2019 (COVID-19), a systemic illness characterized by variably …

Background Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19)
patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill …

Heparin, an old but first-line anticoagulant, has been used over a century. It is a
heterogeneous, linear, highly sulfated, anionic glycosaminoglycan with a broad distribution …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

An analysis of published data appertaining to the cytokine storms of COVID-19, H1N1
influenza, cytokine release syndrome (CRS), and macrophage activation syndrome (MAS) …